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Challenging the Dogmas of Outpatient Parenteral Antimicrobial Therapy Through a Randomized Controlled Trial
Background. Outpatient parenteral antimicrobial therapy (OPAT) has shifted from being a novel concept to an accepted model of care for some conditions. However, concerns remain that have limited its broader roll out: the use of daily ceftriaxone regarding its efficacy and impact on antibiotic resistance, intravenous (IV) catheter complications, risk of treating an acute infection directly from the emergency room (ER), and concern that OPAT has shifted the burden of cost from hospitals to patients. We aimed to address these questions with the first randomized controlled trial (RCT) of OPAT efficacy in children: comparing OPAT directly from the ER using IV ceftriaxone with hospitalization using IV flucloxacillin for moderate/severe cellulitis.
Methods. The RCT was set at a tertiary pediatric hospital from January 2015 to June 2017. Inclusion criteria: children 6 months-18 years with uncomplicated cellulitis needing IV antibiotics. Patients were randomized to ceftriaxone via OPAT at home or flucloxacillin in hospital, using a peripheral catheter. Primary outcome: treatment failure within 48 hours due to lack of improvement or adverse events. Secondary outcomes: complications, readmission, acquisition of nasal and stool-resistant bacteria and costs.
Results. A total of 188 children were randomized: 93 to OPAT and 95 to hospital. In the intention-to-treat population, there was no difference in treatment failure between OPAT and hospital (2% vs. 7%, P = 0.09). Per protocol, OPAT had less failure (1% vs. 8%, P = 0.03). There was no increased acquisition of MRSA, ESBL, VRE or C. difficile with OPAT compared with in hospital at 1 week or 3 months (P > 0.05). Complication rates were similar (6% vs. 7%, P = 0.78), and repeat IV catheterization was less with OPAT (3% vs. 15%, P = 0.002). Readmission was 1% on OPAT. The cost to families was significantly less with OPAT (AUD213 vs. AUD733, P < 0.001).
Conclusion. Despite the acuity of the infection, OPAT with IV ceftriaxone for moderate/severe cellulitis in children is efficacious with complications and readmissions no different from hospital care with IV flucloxacillin. Short-term ceftriaxone use in healthy children on OPAT is not associated with increased acquisition of resistant organisms, and has reduced burden of costs to families (ClinicalTrials.gov NCT02334124).
Disclosures. Background. Lyme disease commonly present as arthritis (LA) and may mimic septic arthritis (SA). SA has worse prognosis and requires hospitalization. LA diagnosis guidelines suggest two-tiered algorithm. Results take 3-5 days to return, putting children at risk by mismanagement. For children with acute arthritis, timely recognition improves quality of care.
Methods. We retrieved charts of children with joint complaint in a Lyme endemic region (January 2011-July 2016). We identified SA and LA and characterized presentations. We reviewed all Lyme [anti-VlsE] chemiluminescent immunoassay screens, (January 2015-January 2017). The study was approved by IRB.
Results. We reviewed 705 charts. SA was found in 24 patients, including 5 with knee arthritis. Seventy-two had confirmed LA, 70 in the knee [fig 1] . Laboratory and physical findings are summarized in Table 1 . 2,341 anti-VlsE screens reviewed. 92% were negative. Of the 88 patients with high levels (>8), 53% had arthritis [ Figure 2 ].
Conclusion. In children with knee arthritis, LA is 14 times more common than SA. Delayed diagnosis put many children at risk of mismanagement. Physical and laboratory findings may direct clinical suspicion but are limited when differentiating between LA and SA. High value anti-VlsE screens suggest symptomatic disease and may confirm LA diagnosis within hours. This correlates with the hypothesis of this B. burgdoferi's surface protein's role in immune evasion, leading to dysregulated inflammation. Background. Total hip (THA) and total knee (TKA) arthroplasty are the most common elective surgical procedures performed in the USA. Most are performed in older adults and lead to improved quality of life; however, complications such as prosthetic joint infection (PJI) can occur. Little is known regarding the mortality attributable to PJI after THA or TKA.
Methods. Claims data from the 2004 to 2012 Medicare 5% sample Standard Analytic Files were used to find eligible beneficiaries, with ICD-9-CM procedure codes identifying primary THA (81.51) or primary TKA (81.54), and diagnosis code 996.66 indicating PJI during the year following the procedure. Inclusion criteria included traditional Medicare coverage during the year prior and two years following the procedure and original reason for entitlement due to age. Exclusion criteria included missing surgery date, additional primary procedures within 1 year, and PJI diagnosis prior or during index stay. The attributable mortality of PJI during the 2 years following primary hip and knee arthroplasty among Medicare beneficiaries was calculated by fitting Kaplan-Meier survival curves and performing a time-dependent analysis based on PJI timing using an Extended Cox Proportion Hazard model.
Results. A total of 248,340 hip and knee arthroplasties were performed on 5% Medicare sample beneficiaries between 2005 and 2012. The final cohort included 117,515 arthroplasties: 37,098 (32%) hip and 80,429 (68%) knee, of which 80,377 (68%) were performed in women and 61,807 (53%) in patients greater than 75 years of age. PJI was diagnosed in one percent of hip (n = 338) and knee (n = 726) arthroplasties, of which 112 (11%) died. The crude mortality rate was 3.2 (95% CI: 2.3,4.2) and 3.7 (95% CI: 2.9,4.8) times greater in patients with PJI than without PJI following THA and TKA, respectively. Controlling for comorbid conditions and the time-dependent nature of PJI, the risk of death with PJI was 2.5 (95% CI: 1.9,3.3) times higher following THA and 2.6 (95% CI: 2.0,4.3) times higher following TKA than for non-PJI.
Conclusion. Medicare beneficiaries who develop PJI after THA or TKA have an increased risk of death during the first 2 years following the procedure, supporting the importance of better understanding risk factors and preventing PJI following these elective procedures.
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